摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3'-chloro-[1,1'-biphenyl]-2-sulfonamide | 1350725-94-8

中文名称
——
中文别名
——
英文名称
3'-chloro-[1,1'-biphenyl]-2-sulfonamide
英文别名
2-(3-Chlorophenyl)benzene-1-sulfonamide;2-(3-chlorophenyl)benzenesulfonamide
3'-chloro-[1,1'-biphenyl]-2-sulfonamide化学式
CAS
1350725-94-8
化学式
C12H10ClNO2S
mdl
——
分子量
267.736
InChiKey
IVPOLULWJOBXNR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    17
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    68.5
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    3'-chloro-[1,1'-biphenyl]-2-sulfonamide 、 6-(dimethylamino)-1-benzothiophene-2-carboxylic acid 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 72.0h, 以20 mg的产率得到N-(3'-chloro[1,1'-biphenyl]-2-sulfonyl)-6-(dimethylamino)-1-benzothiophene-2-carboxamide
    参考文献:
    名称:
    [EN] ACYL SULFONAMIDES FOR TREATING CANCER
    [FR] ACYLSULFONAMIDES POUR LE TRAITEMENT DU CANCER
    摘要:
    本发明提供了一般式(I)的酰基磺酰胺化合物:其中X、R1、R2、R3、R4、R5、R6、Ra和Rb如本文所述和定义的那样,制备所述化合物的方法,用于制备所述化合物的有用中间体化合物,包含所述化合物的药物组合物和组合物,以及利用所述化合物制造用于治疗或预防疾病的药物组合物,特别是治疗或预防过度增殖性疾病的药物组合物,作为唯一药剂或与其他活性成分结合使用,以及治疗和/或预防疾病的方法,特别是癌症,更特别是KAT6A和/或KAT6B在局部扩增的癌症,所述方法包括向需要的受试者施用至少一种式(I)化合物的有效量。
    公开号:
    WO2020216701A1
  • 作为产物:
    描述:
    3-氯苯硼酸 在 bis-triphenylphosphine-palladium(II) chloride 、 、 sodium carbonate 、 三苯基膦 作用下, 以 甲醇丙醇 为溶剂, 反应 20.0h, 生成 3'-chloro-[1,1'-biphenyl]-2-sulfonamide
    参考文献:
    名称:
    [EN] ACYL SULFONAMIDES FOR TREATING CANCER
    [FR] ACYLSULFONAMIDES POUR LE TRAITEMENT DU CANCER
    摘要:
    本发明提供了一般式(I)的酰基磺酰胺化合物:其中X、R1、R2、R3、R4、R5、R6、Ra和Rb如本文所述和定义的那样,制备所述化合物的方法,用于制备所述化合物的有用中间体化合物,包含所述化合物的药物组合物和组合物,以及利用所述化合物制造用于治疗或预防疾病的药物组合物,特别是治疗或预防过度增殖性疾病的药物组合物,作为唯一药剂或与其他活性成分结合使用,以及治疗和/或预防疾病的方法,特别是癌症,更特别是KAT6A和/或KAT6B在局部扩增的癌症,所述方法包括向需要的受试者施用至少一种式(I)化合物的有效量。
    公开号:
    WO2020216701A1
点击查看最新优质反应信息

文献信息

  • Palladium-Catalyzed Site-Selective C−H Functionalization of Weakly Coordinating Sulfonamides: Synthesis of Biaryl Sulfonamides
    作者:Rajeshwer Vanjari、Tirumaleswararao Guntreddi、Krishna Nand Singh
    DOI:10.1002/asia.201501385
    日期:2016.3.4
    A novel and site selective C−H functionalization of unsubstituted sulfonamides has been developed for the synthesis of ortho aryl sulfonamides. The reaction involves highly regioselective ortho mono arylation of weakly coordinating SO2NH2 directing group by means of aryl iodides. Palladium acetate in the presence of silver(I) oxide is found to be the most effective catalytic system.
    未取代的磺酰胺的一个新颖和选择性的位点C-H官能化已开发用于合成邻芳基磺酰胺。该反应涉及借助于芳基碘化物的弱配位的SO 2 NH 2导向基团的高度区域选择性邻位单芳基化。发现在氧化银(I)存在下的乙酸钯是最有效的催化体系。
  • [EN] SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER<br/>[FR] ACYLSULFONAMIDES SUBSTITUÉS POUR LE TRAITEMENT DU CANCER
    申请人:BROAD INST INC
    公开号:WO2022081842A1
    公开(公告)日:2022-04-21
    The present invention provides acyl sulfonamide compounds of general formula (I): (I) in which R1, R2, R3, R4, R5 and R6 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients as well as methods of treatment and/or prophylaxis of diseases, particularly cancer, more particularly cancer in which KAT6A and/or KAT6B is focally amplified, said method comprising administering an effective amount of at least one compound of formula (I) to a subject in need thereof.
    本发明提供了一般式(I)的酰基磺酰胺化合物:(I)其中R1、R2、R3、R4、R5和R6如本文所述和定义的,制备所述化合物的方法,用于制备所述化合物的有用中间体化合物,包含所述化合物的药物组合物和配方,以及利用所述化合物制造用于治疗或预防疾病的药物组合物,特别是用作唯一药剂或与其他活性成分结合的方法,以及治疗和/或预防疾病的方法,特别是癌症,更具体地说是KAT6A和/或KAT6B局部扩增的癌症,所述方法包括向需要的受试者投与至少一种式(I)化合物的有效剂量。
  • ACYL SULFONAMIDES FOR TREATING CANCER
    申请人:Bayer Aktiengesellschaft
    公开号:US20220226279A1
    公开(公告)日:2022-07-21
    The present invention provides acyl sulfonamide compounds of general formula (I): in which X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6′ R a and R b are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients as well as methods of treating and/or prophylaxing diseases, particularly cancer, more particularly cancer in which KAT6A and/or KAT6B is focally amplified, said method comprising administering an effective amount of at least one compound of formula (I) to a subject in need thereof.
  • [EN] ACYL SULFONAMIDES FOR TREATING CANCER<br/>[FR] ACYLSULFONAMIDES POUR LE TRAITEMENT DU CANCER
    申请人:BAYER AG
    公开号:WO2020216701A1
    公开(公告)日:2020-10-29
    The present invention provides acyl sulfonamide compounds of general formula (I): in which X, R1, R2, R3, R4, R5, R6, Ra and Rb are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients as well as methods of treating and/or prophylaxing diseases, particularly cancer, more particularly cancer in which KAT6A and/or KAT6B is focally amplified, said method comprising administering an effective amount of at least one compound of formula (I) to a subject in need thereof.
    本发明提供了一般式(I)的酰基磺酰胺化合物:其中X、R1、R2、R3、R4、R5、R6、Ra和Rb如本文所述和定义的那样,制备所述化合物的方法,用于制备所述化合物的有用中间体化合物,包含所述化合物的药物组合物和组合物,以及利用所述化合物制造用于治疗或预防疾病的药物组合物,特别是治疗或预防过度增殖性疾病的药物组合物,作为唯一药剂或与其他活性成分结合使用,以及治疗和/或预防疾病的方法,特别是癌症,更特别是KAT6A和/或KAT6B在局部扩增的癌症,所述方法包括向需要的受试者施用至少一种式(I)化合物的有效量。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐